Vinyl acetate monomer (VAM), an important chemical intermediate in industry, is produced by the well-established commercial process of acetoxylation of ethylene with Pd-Au/SiO and a KOAc promoter. No paper has since decades defined the true effects of Au and KOAc, despite numerous attempts to clarify them. The role of subsurface carbon as a catalyst booster for enhanced catalytic performance in VAM synthesis was found by us for the first time. X-ray diffraction and X-ray absorption fine structure studies revealed that carbon atoms spontaneously doped into the Pd-Au alloy lattice while maintaining the alloy's size, metallic state, and alloy composition. Additionally, during the process, the KOAc addition dramatically raised the equilibrium carbide fraction. Because of the high carbide fraction, KOAc/PdAu/SiO had a 5.6-fold higher formation rate (89.0% selectivity) than PdAu/SiO (69.2% selectivity) due to high carbide fraction. Surprisingly, kinetic and theoretical analyses showed that the coupling of acetate and ethylene, which is a rate-determining step, is effectively promoted by the synergistic contributions of Au (electronic/geometric effects) and interstitial carbon (electronic effect). Additionally, the synergy inhibits ethylene dehydrogenation, which ultimately slows the formation of CO. The contentious debates about the roles of Au and KOAc in the acetoxylation of ethylene have been resolved thanks to experimental and theoretical insights into the roles of Pd-Au formation, Au/Pd ratio, and interstitial carbon atoms. These insights also open the door for the logical design of catalysts with desirable catalytic performance.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/jacs.2c11481 | DOI Listing |
Objectives: We aimed to assess the anti-mutated citrullinated vimentin (anti-MCV) antibodies in RA patients' serum and to explore their association with interstitial lung disease (ILD).
Methods: Eighty rheumatoid arthritis (RA) patients and forty healthy controls were included in this case-control study. Of these patients, forty had ILD, and forty without ILD.
Respir Res
December 2024
National Jewish Health, Denver, USA.
Background: We sought consensus among practising respiratory physicians on the prediction, identification and monitoring of progression in patients with fibrosing interstitial lung disease (ILD) using a modified Delphi process.
Methods: Following a literature review, statements on the prediction, identification and monitoring of progression of ILD were developed by a panel of physicians with specialist expertise. Practising respiratory physicians were sent a survey asking them to indicate their level of agreement with these statements on a binary scale or 7-point Likert scale (- 3 to 3), or to select answers from a list.
Eur J Radiol
December 2024
Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Objective: To assess whether CT style conversion between different CT vendors using a routable generative adversarial network (RouteGAN) could minimize variation in ILD quantification, resulting in improved functional correlation of quantitative CT (QCT) measures.
Methods: Patients with idiopathic pulmonary fibrosis (IPF) who underwent unenhanced chest CTs with vendor A and a pulmonary function test (PFT) were retrospectively evaluated. As deep-learning based ILD quantification software was mainly developed using vendor B CT, style-converted images from vendor A to B style were generated using RouteGAN.
Quant Imaging Med Surg
December 2024
Capital Medical University, Beijing, China.
Background: Rapidly progressive interstitial lung disease (RP-ILD) significantly impacts the prognosis of patients with idiopathic inflammatory myopathies (IIM). High-resolution computed tomography (HRCT) is a crucial noninvasive technique for evaluating interstitial lung disease (ILD). Utilizing quantitative computed tomography (QCT) enables accurate quantification of disease severity and evaluation of prognosis, thereby serving as a crucial computer-aided diagnostic method.
View Article and Find Full Text PDFRheumatology (Oxford)
December 2024
Division of Rheumatology, University of Colorado Anschutz Medical Campus, Denver, CO.
Background: Interstitial lung disease (ILD) develops in 5-10% of patients with rheumatoid arthritis (RA) and contributes significantly to morbidity and mortality, particularly in those with a fibrotic phenotype. Yet, biomarkers to reliably identify RA patients with underlying pulmonary fibrosis are inadequate. Herein, we used sputum to identify lung-based biomarkers that distinguish RA patients with underlying pulmonary fibrosis and may better inform underlying pathogenesis in RA-ILD.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!